Literature DB >> 3253051

A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.

G Segre1, D Cerretani, D Cerri, L Moltoni.   

Abstract

The kinetics of a new fluoroquinolone, rufloxacin (MF-934), have been studied in rats, dogs and monkeys. The drug is characterized by a long half-life, which is equal to 24, 12 and 15 h in the three species, respectively. A high tissue plasma ratio is observed in rats. In these animals the bioavailability is equal to 60%. The drug does not appear to enter the brain in rats and in monkeys, even after repeated administration (90 days). No accumulation is seen in rats and in monkeys after repeated daily administration for 90 days. The urinary excretion of unmodified drug is equal to about 27 and 40% of the dose in the rat and in the monkey, respectively.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3253051

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN： 0378-6501


  9 in total

1.  Pharmacokinetics of rufloxacin in healthy volunteers.

Authors:  G Segre; D Cerretani; L Moltoni; R Urso
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

Authors:  B P Imbimbo; G Broccali; M Cesana; F Crema; G Attardo-Parrinello
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

4.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

5.  Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.

Authors:  S M Qadri; Y Ueno; G Postle; D Tullo; J San Pedro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

6.  Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.

Authors:  J C Kisicki; R S Griess; C L Ott; G M Cohen; R J McCormack; W M Troetel; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

7.  High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans.

Authors:  T B Vree; M van den Biggelaar-Martea; B P Imbimbo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

8.  Pharmacokinetics of rufloxacin in patients with impaired renal function.

Authors:  G Perry; T G Mant; P J Morrison; S Sacks; J Woodcook; R Wise; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections.

Authors:  R Rimoldi; M Fioretti; A Albrici; B P Imbimbo
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.